- Home
- ASBP vs CRIS Comparison
ASBP vs CRIS Comparison
Compare ASBP & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASBP | CRIS |
|---|---|---|
| Founded | 2021 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 14.6M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | ASBP | CRIS |
|---|---|---|
| Price | $0.10 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | ★ 56.6M | 110.0K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,941.00 | ★ $11,650,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | N/A | $8.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $0.07 | $1.02 |
| 52 Week High | $15.80 | $4.50 |
Technical Indicators
Market Signals| Indicator | ASBP | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 33.53 | 40.13 |
| Support Level | $0.07 | $1.29 |
| Resistance Level | $0.10 | $1.41 |
| Average True Range (ATR) | 0.01 | 0.12 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 55.40 | 23.54 |
Price Performance
Historical ComparisonAbout ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.